dabrafenib,trametinib
novartis
['mekinist', 'tafinlar', 'novartis']
with asco data, novartis' tafinlar-mekinist heads toward fda for braf-mutant pediatric brain cancer. the targeted agents significantly improved response rates and survival times versus up-front chemotherapy for braf v600e-mutant pediatric low-grade... 